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Primary Papillary Serous Carcinoma of the Peritoneum: A Case 
of Complete Remission of Bulky Peritoneal Disease After 
Chemotherapy 
Walid A. Saleh, MD,* Cosmas J. M. Van de Ven, MD,* and Wooshin Kim, MD' 
Peritoneal papillary serous carcinoma is a rare tumor that involves ihe surface ofthe pelvic andior 
abdominal peritoneum. Long-ierm survival among patients with this tumor has been rare. Most 
patients with this cancer have been treated with debulking surgeiy and postoperative chemotherapy. 
A case of incompletely resected peritoneal papillary serous carcinoma with a complete response to 
cisplatin-based chemotherapy is reported. Subsequent laparotomy revealed no residual tumor. This 
case suggests that primary chemotherapy may be successful in treating unresectable primary 
papillary serous tumors ofthe peritoneum. (Henry Ford Hosp MedJ 1992;40:136-8) 
Papillary serous carcinoma (PSC) of the peritoneum was first described by Swerdlow (1) in 1959. It involves diffusely the 
peritoneum, histologically resembles PSC of the ovary, but ei-
ther spares the surface of the ovary or involves it only micro-
scopically (2). About 130 cases have been described under a va-
riety of names including mesotheliomas, mesodermoma, perito-
neal PSC, papillary carcinoma from extraovarian tissue, serous 
surface papillary carcinoma of the ovary, and peritoneal car-
cinomatosis of unknown primary site. There is still no consen-
sus regarding nomenclature, histogenesis, immunohistochemi-
cal characteristics, clinical behavior, and treatment. 
Case Report 
A 75-year-old white female, gravida 3, para 3, underwent surgery in 
a local hospital for possible incarcerated inguinal hernia. There was a 
four-month history of gradually increasing abdominal girth, and on ad-
mission her abdomen was markedly distended. She denied any change 
in weight. Physical examination confirmed the presence of abdominal 
distension and tympany and hyperactive bowel sounds and disclosed a 
3 cm ovoid nontender, nonreducible mass in the right inguinal area. On 
admission, x-rays and laboratory tests were reportedly normal. With 
the patient under spinal anesthesia, a right incarcerated femoral hernia 
sac was opened. During exploration, muhiple polypoid implants sug-
gestive of carcinomatosis along with a large amount of brown-colored 
peritoneal fluid and necrotic tumor material were encountered. There 
was no evidence of bowel in the hernia. The incision was extended and 
abdominal exploration revealed marked ascites, diffuse tumor infiltra-
tion of the entire pelvis and small bowel, and "caking" of the lower 
third of the omentum. The liver and upper abdominal structures were 
not involved, and there was no evidence of bowel obstruction. After 
multiple biopsies were taken from the omentum, hernial sac, and pelvic 
peritoneum (Figure), the incision was closed as the tumor was consid-
ered to be unresectable. The postoperative course was uneventful ex-
cept for mild ileus. On the recommendation of the medical oncologist, 
the patient received nine courses of Cytoxan and carboplatin over a total 
of eight months following the usual protocol for ovarian carcinoma. 
Follow-up visits revealed that the patient was doing well with no clini-
cal evidence of disease. The carcinoembryonic antigen (CEA) and CA 
125 levels were consistently normal. After completion of the chemo-
therapy, abdominal computed tomography (CT) revealed a 1 cm soft 
tissue density at the level of the cecum, which was unchanged from a 
previous CT one month earlier. 
The patient was referred to Henry Ford Hospital for a second explor-
atory laparotomy 11 months after the original surgery. She underwent 
lysis of adhesions, cytology washings, total abdominal hysterectomy 
and bilateral salpingo-oophorectomy, selective pelvic and paraaortic 
lymph node dissection, omentectomy, and repair of right inguinal her-
nia. There were dense adhesions around the bowel and adnexae. Both 
ovaries were atrophic, about 1 cm in greatest diameter. A 2 cm nodule 
was found in the right pelvic side wall, posterior to the cecum, with 
multiple small yellowish nodules on the pelvic floor and peritoneal sur-
face. Overall there was no gross evidence of disease. The pelvic wash-
ings and multiple biopsies were negative. The patient was alive and free 
of disease 11 months after her second exploration. 
Discussion 
Many previous studies indicate that patients with primary 
PSC have a worse prognosis than do those with ovarian cancer. 
It is unclear whether this worse prognosis is due to the advanced 
disease which is frequentiy found in this tumor or to unknown 
inherent biological characteristics. We present a case of primary 
PSC and extensive peritoneal involvement with absence of dis-
ease surgically documented after chemotherapy. 
Malignant tumors involving the peritoneum are usually due 
to metastatic ovarian carcinoma, tn rare cases, no primary tumor 
Submitted for publication; July 22, 1991. 
Accepled for publication; December 19, 1991. 
*Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Henry 
Ford Hospital. 
tMatemal-Felal Medicine, Duke University Medical Center, Durham, NC. 
*Address correspondence to Dr. Saleh, Departmenl of Obstetrics and Gynecology, Henry 
Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202. 
136 Henry Ford Hosp Med J—Vol 40, Nos 1 & 2. 1992 Cure of Unresecled Peritoneal Cancer—Saleh et al 
can be found and a primary tumor of the peritoneum must be 
considered. Of course other primary tumors must be ruled out. 
As in ovarian serous tumors, benign, borderiine, and malignant 
variants of papillary serous tumors have been reported (3). Be-
nign or borderline peritoneal tumors must be differentiated mor-
phologically from mesotheliomas (4). PSC is frequentiy de-
scribed microscopically as showing mitotic figures and many 
psammoma bodies (5,6). Most PSC tumors have at teast a few 
celts that show cytoplasmic or surface mucin and stain posi-
tively for keratin and epithelial membrane antigen. Other mark-
ers such as Leu-Ml, B72.3, vimentin, HPLAP, and CEA are 
found in a small percentage of cells (6,7). In fact, on the basis of 
light microscopy and histochemical and immunohistochemical 
characteristics, PSC cannot be differentiated from ovarian carci-
noma. This lack of cytochemical discrimination is explained by 
the common histogenesis of these neoplasms. Both the perito-
neal mesothelium and the surface epithelium of the ovary de-
velop from the embryonic coelomic epithelium. The commonly 
accepted theory for the origin of peritoneal papillary carcinoma 
is that it arises directly from the mesodermal lining of the ab-
dominal cavity in response to an unknown oncogenic stimulus 
(4,8). On the other hand, some believe that PSC arises from em-
bryonic rest cells (5). In any event, the coelomic origin of these 
tumors explains their resemblance in many respects to ovarian 
cancer. The fact that PSC has occurred in patients after bilateral 
salpingo-oophorectomy supports the concept of its peritoneal 
origin (9). 
PSC affects only women, whose median age is about 60 years 
(4,10), Abdominal pain and distension are the most common 
presenting symptoms (6,9) while a palpable mass is uncommon 
(4) . Radiological studies including CT are usually not helpful in 
diagnosis (6). In most cases the entire mesothelial surface is in-
volved and the tumor is rarely predominant in or limited to the 
pelvis. Generally the ovaries are invotved only superficially and 
are of normal size. When the tumor invades the ovaries, one en-
counters superficial involvement as well (6). PSC frequentiy in-
volves the submesothelium, but deep invasion into the abdomi-
nal or pelvic organs or either local or distant metastases are rare 
(5) . Spread of the disease outside the abdominal cavity produc-
ing malignant pleural effusion has been described (9). Ascitic 
fluid, when present, usually contains malignant cells. 
The median survival time of patients with PSC is between 11 
and 24 months, simitar to those of the same age group who have 
ovarian cancer (2,9). Some have found that peritoneal tumor has 
a worse prognosis than ovarian cancer (11,12). White most se-
ries report only a few long-term survivors. Ransom et al (13) de-
scribed three patients who lived over six years. Chen and Flam 
(3) atso reported long-term survival after cisplatin-based che-
motherapy. These patients had undergone optimal debulking 
surgery followed by cytoxan-cisplatin chemotherapy. 
There is no consensus as to the best therapy for peritoneal car-
cinoma, but most authors prefer to treat it in the same manner as 
ovarian cancer (2,4,9). Complete clinical response to postopera-
tive chemotherapy has been reported in 20% to 25% of patients 
(2,4,6), but not all respond so favorably (13). Patients treated 
with combination chemotherapy do better than those treated 
with single agents and cisplatin-based regimens seem to be 
Figure—Papillary serous carcinoma ofthe peritoneum (hema-
toxylin-eosin stain, X50). 
more effective (4). Contrary to other authors, Fromm et at (4) in 
their large series of 74 patients found that neither chronologic 
age nor the presence of residual disease after cytoreduction de-
termined prognosis. This finding is in contrast with that found in 
ovarian cancer. Fromm et al concluded that the absence of mito-
ses represented a favorable prognostic factor. Lele et al (2) de-
scribed one patient with complete response to cisplatin, bleo-
mycin, and cytosine arabinoside administered intraperitoneally. 
Most studies conceming PSC of the peritoneum are retrospec-
tive and there is no staging system. Few reports allow conclu-
sions about therapy, most focus on the pathology, and all are ret-
rospective in nature. Only prospective studies conducted in 
multiinstitutional clinical trials can provide reliable data about 
the natural history of this disease. The vatue of intraperitoneal 
chemotherapy must be carefully investigated. Our case suggests 
that chemotherapy may be successful in treating unresectable 
primary PSC of the peritoneum. 
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